Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) 5-Year EBITDA Growth Rate : 31.70% (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Chugai Pharmaceutical Co 5-Year EBITDA Growth Rate?

Chugai Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was $0.20.

During the past 12 months, Chugai Pharmaceutical Co's average EBITDA Per Share Growth Rate was -0.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 14.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 31.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Chugai Pharmaceutical Co was 51.10% per year. The lowest was -12.60% per year. And the median was 7.15% per year.

Competitive Comparison of Chugai Pharmaceutical Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.

Chugai Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Chugai Pharmaceutical Co (OTCPK:CHGCY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Chugai Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CHGCF:USA 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines

From GuruFocus

T. Rowe Price Japan Fund Makes 4 New Buys in 3rd Quarter

By David Goodloe David Goodloe • 10-19-2016

T. Rowe Price Japan Fund Comments on Chugai Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 06-19-2020

Jean Hynes Adds to Chugai Pharmaceutical Stake

By Kyle Ferguson Kyle Ferguson • 08-22-2016

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

By PRNewswire PRNewswire • 03-02-2023

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020